Recent News

Low to be honored by American Lung Association for cancer-fighting invention

March 21, 2024

The American Lung Association in Indiana will honor Purdue University researcher Philip Low on April 13 at its annual gala in Indianapolis for his invention of CYTALUX, which helps in the fight against lung cancer. Low, Purdue’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in the College of Science, developed CYTALUX, an FDA-approved fluorescent marker that illuminates lung cancer cells during surgery. This allows surgeons to quickly distinguish malignant cells from healthy cells and confirm that all malignant cells have been removed. Total removal is key to preserving the lives of lung cancer patients.

Low to be honored by American Lung Association for cancer-fighting invention

Neuroprotection by acrolein sequestration through exogenously applied scavengers and endogenous enzymatic enabling strategies in mouse EAE model

March 12, 2024

Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the brain and spinal cord which affects approximately 2.5 million individuals worldwide, often striking young adults without warning1,2,3,4. Patients experience a variety of motor, sensory, and cognitive deficiencies1,3,5. Unfortunately, due to the incomplete understanding of the etiology of MS, current available therapies remain largely unsatisfactory, as they mainly focus on immunomodulation or symptomatic relief with limited success2. As such, the long-term trajectory and prognosis for most MS patients, a continual worsening of symptoms until death, is not significantly altered by the current standards of care6,7,8,9,10,11. Thus, a major priority in this field is to identify key pathological factors that can provide new and effective therapeutical targets to deter the pathological progression of MS. There is strong evidence that reactive oxygen species are the mediators of MS pathology12,13,14,15,16. However, antioxidant therapeutic strategies alone have shown limited success in mitigating disease progression14,17,18. Recently, emerging scientific findings suggest that reactive aldehydes, products of free radical-instigated lipid peroxidation, may play a critical role in the pathogenesis of MS19,20,21,22,23. Acrolein, a toxic reactive aldehyde, is both a product and catalyst of oxidative stress and inflammation24,25. As such, it can induce a vicious cycle wherein it begets and worsens the mechanisms by which it is created, thereby amplifying its effects24,25,26. Therefore, acrolein may provide a better target to suppress oxidative stress in MS.

Neuroprotection by acrolein sequestration through exogenously applied scavengers and endogenous enzymatic enabling strategies in mouse EAE model

Purdue Researchers Investigate Noninvasive Method For Sampling Drug Response

March 9, 2024

Tao and his associates have begun developing a patent-pending EV method for detecting proteins involved in drug absorption, distribution, metabolism and excretion (ADME). “If successful, this would be tremendously beneficial, especially for drug development companies,” Tao said.

Purdue Researchers Investigate Noninvasive Method For Sampling Drug Response

Purdue University: Amplified Sciences Secures $108K Flywheel Fund Investment For Development Of Pancreatic Cancer Diagnostics

March 9, 2024

Amplified Sciences, a clinical-stage life sciences diagnostic company that licenses Purdue University innovations, has received $108,000 in two investments from the Flywheel Fund to develop its tests for early, more accurate detection of challenging diseases, starting with pancreatic cancer. Amplified Sciences’ diagnostic tests are based on technology invented by V. Jo Davisson, professor of medicinal chemistry and molecular pharmacology in Purdue University’s College of Pharmacy and a faculty member of the Purdue Institute for Cancer Research and the Purdue Institute for Drug Discovery. Davisson serves as the company’s chief scientific officer. The company licenses Davisson’s intellectual property through the Purdue Innovates Office of Technology Commercialization.

Purdue University: Amplified Sciences Secures $108K Flywheel Fund Investment For Development Of Pancreatic Cancer Diagnostics

Cracking the Code on a Universal Flu Vaccine

March 8, 2024

Led by Dr. Suresh Mittal, Distinguished Professor of Virology in the Purdue University College of Veterinary Medicine, researchers are working on the development of a universal vaccine, one that would offer protection against all forms of influenza A that infect humans, regardless of the strain. Such a vaccine could eliminate the need to reformulate seasonal flu vaccines and provide the health care system with a jumpstart in combatting the next flu pandemic.

Cracking the Code on a Universal Flu Vaccine

Purdue Launches Search for Successor to Pioneering Veterinary Medicine Dean Willie Reed Who will Step Down

March 8, 2024

An advisory committee has been named to assist in the search for a successor to Dr. Willie Reed, who will step down June 30, after 17 years of leadership as dean of the Purdue University College of Veterinary Medicine and 25 total years of service to the university. A celebration of Dean Reed’s legacy will take place later this semester.

Purdue Launches Search for Successor to Pioneering Veterinary Medicine Dean Willie Reed Who will Step Down

Cracking the Code on a Universal Flu Vaccine

March 8, 2024

Promising initial research could lead to more effective seasonal flu shots and ward against future pandemics

Cracking the Code on a Universal Flu Vaccine

Purdue researchers see possible link with dog, human cancer treatments

March 6, 2024

In the first experiment of its kind, Purdue University researchers treated canines diagnosed with cancer using chemotherapy to see if their response could lead to future treatment for human cancer patients. Chemoresistance, a patient's adverse reaction to chemotherapy, can lessen remission and survival time. Michael Childress, professor of comparative oncology in the College of Veterinary Medicine at Purdue University, said the dogs were chosen because they had diffuse large B-cell lymphoma. The condition mimics the cancer phenotypes or traits that would be needed when treating human cancer patients.

Purdue researchers see possible link with dog, human cancer treatments

Biodynamic Imaging Shows Promise for Predicting Response to Chemotherapy

March 5, 2024

Purdue University researchers are advancing a new technology that uses light waves to detect chemotherapy resistance in cancer cells into interventional clinical trials following positive results in a human pilot study. In February, David Nolte, a professor of physics at Purdue, and his colleagues published in Scientific Reports the results of a study of digital holographic optical coherence imaging (DHOCI) as a method to detect treatment resistance in tissue biopsy samples from humans and dogs given chemotherapy.

Biodynamic Imaging Shows Promise for Predicting Response to Chemotherapy

FROM EXPLORING CELLS TO HELPING RESEARCHERS, HHS DISTINGUISHED ALUMNA ADVANCES CANCER RESEARCH

March 5, 2024

From studying animal science to elevating cancer research to helping health science investigators, Purdue University Department of Nutrition Science alumna Lynn Adams has always had one goal in mind: to make an impact. As a program director in the Outcomes Research Branch in the National Cancer Institute’s (NCI) Division of Cancer Control and Population Sciences, Adams helps researchers as they secure National Institutes of Health (NIH) funding to unlock new cancer knowledge and treatments.

FROM EXPLORING CELLS TO HELPING RESEARCHERS, HHS DISTINGUISHED ALUMNA ADVANCES CANCER RESEARCH